Inclusion Criteria:

- Patients with histologically demonstrated prostatic adenocarcinoma.

- Patients never previously treated with hormonal therapy for prostate cancer.

- Patients eligible for hormonal therapy after initial consultation (alone or in
combination with curative treatment).

- Patients agreeing to the collection of personal health data for the purposes of the
study.

- Patients with locally advanced or metastatic prostatic cancer tumours or a biological
recurrence after curative treatment.

Exclusion Criteria:

- Patients participating in a clinical study involving prostate cancer at the time of
inclusion in the investigation.

- Patients having received or currently receiving hormonal treatment for prostate
cancer (surgical castration or other hormonal manipulation, including GnRH receptor
antagonists, antiandrogens, oestrogens, 5 alpha reductase inhibitors).